Agonist anti-tumor activity of anti-CD40 antibodies has previously been proposed to rely on FcγRIIB-mediated antibody cross-linking and promoted signaling in CD40-expressing antigen presenting cells (23, 24) (Table 1; Figure 2B). The gene discussed is CD40; the disease is neoplasm.